{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:19:03Z","timestamp":1649045943134},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:00:00Z","timestamp":1415750400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0112613","type":"journal-article","created":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T19:12:19Z","timestamp":1415819539000},"page":"e112613","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL28B Polymorphism Cannot Predict Response to Interferon Alpha Treatment in Patients with Melanoma"],"prefix":"10.1371","volume":"9","author":[{"given":"Martin","family":"Probst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert F.","family":"Staettermayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Beinhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Pehamberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Kittler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Grabmeier-Pfistershammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,11,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrclinonc.2013.153","article-title":"The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma","volume":"10","author":"HL Kaufman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.10775","article-title":"Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjucant trial E1690","volume":"95","author":"JM Kirkwood","year":"2002","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1158\/1078-0432.CCR-06-1387","article-title":"Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b","volume":"13","author":"W Wang","year":"2007","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00262-008-0466-9","article-title":"Impact of IFNalpha2b upon pSTAT3 and the MEK\/ERK MAPK pathway in melanoma","volume":"57","author":"W Wang","year":"2008","journal-title":"Cancer immunology, immunotherapy: CII"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1479-5876-8-76","article-title":"Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment","volume":"8","author":"PA Ascierto","year":"2010","journal-title":"Journal of translational medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1479-5876-6-62","article-title":"Adjuvant therapy of melanoma with interferon: lessons of the past decade","volume":"6","author":"PA Ascierto","year":"2008","journal-title":"Journal of translational medicine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients","volume":"25","author":"NJ Ives","year":"2007","journal-title":"Journal of clinical oncology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"S Mocellin","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"A Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Y Tanaka","year":"2009","journal-title":"Nature genetics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","article-title":"Interferon signaling and treatment outcome in chronic hepatitis C","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.gastro.2011.09.039","article-title":"Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection","volume":"142(1)","author":"S Beinhardt","year":"2012","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.mayocp.2014.02.009","article-title":"Melanoma resistance: a bright future for academicians and a challenge for patient advocates","volume":"89(4)","author":"AT Slominski","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ijc.24005","article-title":"Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells","volume":"124(6)","author":"A Slominski","year":"2009","journal-title":"Int J Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"JM Kirkwood","year":"1996","journal-title":"Journal of clinical oncology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"JM Kirkwood","year":"2004","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"JM Kirkwood","year":"2000","journal-title":"Journal of clinical oncology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group","volume":"16(4)","author":"H Pehamberger","year":"1998","journal-title":"Journal of clinical oncology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma","volume":"351","author":"JJ Grob","year":"1998","journal-title":"Lancet"},{"key":"ref21","first-page":"CD008955","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma, Cochrane Database Syst Rev","volume":"6","author":"S Mocellin","year":"2013"},{"key":"ref22","first-page":"344","article-title":"Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naive Patients with Chronic Hepatitis C, Clin Gastroenterol Hepatol","volume":"9(4)","author":"AF St\u00e4ttermayer","year":"2011"},{"key":"ref23","first-page":"104","article-title":"Polymorphisms of interferon-\u03bb4 and IL28B- effects on the treatment response to interferon\/ribavirin in patients with chronic hepatitis C, Aliment Pharmacol Ther","volume":"39(1)","author":"AF St\u00e4ttermayer","year":"2014"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"SV Kotenko","year":"2003","journal-title":"Nature immunology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C","volume":"52","author":"TJ Urban","year":"2010","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C","volume":"139","author":"M Honda","year":"2010","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/hep.25647","article-title":"Dysregulation Of Innate Immunity In HCV Genotype 1 IL28B Unfavorable Genotype Patients: Impaired Viral Kinetics And Therapeutic Response","volume":"56(2)","author":"S Naggie","year":"2012","journal-title":"Hepatology"},{"key":"ref28","first-page":"14","article-title":"L-tyrosine and L-DOPA as hormone-like regulators of melanocyte functions, Pigment Cell Melanoma Res","volume":"25(1)","author":"MA Slominski, Zmijewski","year":"2012"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.humpath.2013.02.022","article-title":"Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma","volume":"44(10)","author":"AA Bro\u017cyna","year":"2013","journal-title":"Hum Pathol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","article-title":"Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C","volume":"140","author":"MT Dill","year":"2011","journal-title":"Gastroenterology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","article-title":"Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response","volume":"46","author":"JJ Feld","year":"2007","journal-title":"Hepatology"},{"key":"ref32","article-title":"Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and IL28B are altered by Infection with Hepatitis C virus","author":"N Jilg","year":"2013","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.gastro.2011.12.055","article-title":"HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons","volume":"142(4)","author":"E Thomas","year":"2012","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3748\/wjg.v13.i36.4818","article-title":"Interaction of hepatitis C virus with the type I interferon system","volume":"13(36)","author":"F Weber","year":"2007","journal-title":"World J Gastroenterol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0112613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T01:23:29Z","timestamp":1540344209000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0112613"}},"subtitle":[],"editor":[{"given":"Andrzej T.","family":"Slominski","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,11,12]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0112613","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,12]]}}}